Topic Review
Trimethylamine N-Oxide Production in Physiological and Pathological Conditions
Trimethylamine N-oxide (TMAO) is an amino oxide, produced from the trimethylamine (TMA) through oxidation by some liver enzymes called flavin monooxygenases 1 and 3 (FMO1 and FMO3).
  • 327
  • 14 Feb 2023
Topic Review
Trimethylamine N-Oxide in Normal Cognitive Aging
Trimethylamine-N-oxide (TMAO), a gut microbiota-derived metabolite from dietary precursors, might emerge as a promising biomarker of cognitive dysfunction within the context of brain aging and NCD. TMAO may increase among older adults, Alzheimer’s disease patients, and individuals with cognitive sequelae of stroke. Higher circulating TMAO would make them more vulnerable to age- and NCD-related cognitive decline, via mechanisms such as promoting neuroinflammation and oxidative stress, and reducing synaptic plasticity and function.
  • 522
  • 21 Oct 2022
Topic Review
Trimethylamine N-Oxide
Trimethylamine N-oxide (TMAO) may play a key mediator role in the relationship between the diet, gut microbiota and cardiovascular diseases, particularly in people with kidney failure.
  • 1.1K
  • 11 May 2021
Topic Review
TRIMbody-Away Technique
TRIMbody-Away technique is a novel technology that could be utilized to acute and rapid destruction of specific intracellular proteins. This technology is based on a new type of fusion protein, designated as TRIMbody, by fusing the truncated form of tripartite motif 21 (TRIM21) with the nanobody. The truncated TRIM21 retained only the N-terminal RBCC domain and deleted the C-terminal PRY-SPRY domain. Therefore, TRIMbody possesses the functions of TRIM21 and mAbs, but has much smaller size. TRIMbody-Away technique could expand the landscape of the applications of degrader technologies and provide an alternative approach for potential therapeutic benefit in future.
  • 597
  • 25 Oct 2021
Topic Review
TRIM Proteins
The TRIpartite Motifs (TRIM) protein family is composed of more than 70 known TRIM proteins in humans and mice, which are encoded by approximately 71 genes in humans.
  • 412
  • 07 Apr 2021
Topic Review
Triglyceride/High-Density Lipoprotein Cholesterol Ratio in Metabolic Syndrome
Increased plasma triglycerides (TG) and decreased high-density lipoprotein cholesterol (HDL-C) levels have been associated with metabolic syndrome (MetS) and cardiovascular disease (CVD), and their ratio, TG/HDL-C, has been proposed as a novel biomarker for predicting the risk of both clinical entities.
  • 339
  • 17 Mar 2023
Topic Review
Triggers of Pediatric Migraine
There are three triggers or risk factors for migraines in children and adolescents: stress, sleep poverty, and alimentation (including diet and obesity). Clinicians should advise patients to avoid certain triggers, such as stress and sleep disorders, and make a few conservative dietary changes.
  • 389
  • 26 Oct 2021
Topic Review
Trifarotene
Trifarotene is a new fourth-generation retinoid with a selective action on RAR-γ. 
  • 601
  • 22 Sep 2021
Topic Review
Trientine in Hypertrophic Cardiomyopathy
Trientine, a copper-chelating drug used in the management of patients with Wilson’s disease, demonstrates beneficial effects in patients with hypertrophic cardiomyopathy.
  • 447
  • 10 Feb 2023
Topic Review
Tricuspid Atresia
Tricuspid atresia (TA) is a cyanotic, congenital heart defect (CHD) and is defined as congenital absence or agenesis of the morphologic tricuspid valve. It is the third most common cyanotic CHD, and is the most common cause of cyanosis with left ventricular hypertrophy. The prevalence of TA is estimated to be 2.9% of autopsy cases and 1.4% to 1.5% of the clinical cases of CHD.
  • 2.5K
  • 20 Oct 2021
  • Page
  • of
  • 1349
Video Production Service